局部与玻璃体内应用雷珠单抗的数学模型
研究利用离体猪眼比较局部滴用雷珠单抗联合细胞穿透肽、玻璃体内注射雷珠单抗联合细胞穿透肽及单纯玻璃体内注射雷珠单抗后房水与玻璃体内药物及VEGF浓度变化,并建立常微分方程模型描述各腔室浓度动态。结果显示细胞穿透肽可使局部雷珠单抗穿透角膜,局部治疗可能持续中度抑制玻璃体VEGF,联合治疗有望减少注射频率。
要点
- 离体猪眼实验显示局部雷珠单抗联合细胞穿透肽可使房水雷珠单抗显著升高并伴随房水VEGF显著下降。
- 局部治疗组玻璃体雷珠单抗显著升高但玻璃体VEGF保持不变,玻璃体内治疗组玻璃体雷珠单抗达高浓度并伴随玻璃体VEGF显著下降。
- 数学模型提示局部治疗可能持续中度抑制玻璃体VEGF,玻璃体内治疗提供强抑制但两次治疗间减弱。
核心结论
- 细胞穿透肽可使局部应用的雷珠单抗穿透角膜。
- 玻璃体内联合局部治疗是有前景的方法,局部治疗在注射间期抑制玻璃体VEGF水平,从而可能减少注射频率。
- 若能提高雷珠单抗与VEGF的结合速率或泪液停留时间,治疗效果将增强。
研究设计与样本
- 离体猪眼实验分为三组:局部雷珠单抗联合细胞穿透肽、玻璃体内雷珠单抗联合细胞穿透肽、玻璃体内雷珠单抗。
- 在20分钟、40分钟、1小时和3.5小时用ELISA测量房水和玻璃体中雷珠单抗与VEGF浓度,每组n=3。
- 建立常微分方程模型描述泪液、房水和玻璃体腔室中雷珠单抗、VEGF及其复合物浓度的动态变化。
主要发现
- 局部治疗组房水雷珠单抗水平显著升高,同时房水VEGF显著下降。
- 局部治疗组玻璃体雷珠单抗显著升高,但玻璃体VEGF保持不变。
- 玻璃体内治疗组(联合或不联合细胞穿透肽)玻璃体雷珠单抗达到高浓度,同时玻璃体VEGF显著下降。
- 数学模型提示局部治疗可能持续中度抑制玻璃体VEGF水平,而玻璃体内治疗提供强抑制,但两次治疗间抑制作用减弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Wet age-related macular degeneration (AMD) causes vision loss when vascular endothelial growth factor (VEGF) stimulates blood vessel growth into the light-sensitive retina. Anti-VEGF treatments such as ranibizumab are currently administered to treat wet AMD via intravitreal injections, which are unpleasant, expensive, and risk complications. We explored the efficacy of topically administered ranibizumab, with cell-penetrating peptides (CPPs). METHODS: Ex vivo pig eyes were divided into three groups and treated with (1) topical or (2) intravitreal ranibizumab and CPP, or (3) intravitreal ranibizumab. ELISAs measured ranibizumab and VEGF concentrations in the aqueous and vitreous at 20 min, 40 min, 1 h, and 3.5 h (n = 3, per group). An ordinary differential equation model was formulated to describe the evolving concentrations of ranibizumab, VEGF, and their compounds in the tear, aqueous, and vitreal compartments. RESULTS: Experimental-Topical: aqueous ranibizumab levels increased significantly, coincident with a significant drop in aqueous VEGF. Vitreal ranibizumab increased significantly, while vitreal VEGF remained constant. Intravitreal (with and without CPP): vitreal ranibizumab reached high concentrations, coincident with a significant drop in vitreal VEGF. Mathematical-topical treatment may provide sustained, moderate suppression of vitreal VEGF levels, while intravitreal treatment provides strong suppression, which lessens between treatments. CONCLUSIONS: CPP allows topical ranibizumab to penetrate the cornea. Combined intravitreal/topical treatment presents a promising approach; topical treatment suppresses vitreal VEGF levels between injections and thereby potentially reduces the frequency of injections. Treatment efficacy would be enhanced if ranibizumab's rate of binding to VEGF or tear residence time could be increased.
引用
- Roberts PA, Thomas CN, Bellamy Plaice G, et al. Mathematical Models of Topically and Intravitreally Applied Ranibizumab. Invest Ophthalmol Vis Sci. 2025. PMID: 40833326. doi:10.1167/iovs.66.11.45
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。